Circulating microRNAs expression profile in newly diagnosed and imatinib treated chronic phase–chronic myeloid leukemia

Chronic myeloid leukemia (CML) is a stem cell derived malignant disorder result of translocation t(9;22)(q34;q11) called Philadelphia chromosome (Ph+). microRNAS (miRNAs) are involved in several biological processes, altering the progression of various pathologies, including CML. This study evaluate...

Full description

Bibliographic Details
Authors: Ferreira, Letícia Antunes Muniz [UNESP], Capannacci, Juliana, Hokama, Newton Key [UNESP], Nogueira, Célia Regina [UNESP], Ceccarelli, Michele, Cerulo, Luigi, D’Angelo, Fulvio, de Oliveira Montandon Hokama, Paula [UNESP]
Format: article
Status:Published version
Publication Date:2018
Country:Brasil
Institution:Universidade Estadual Paulista (UNESP)
Repository:Repositório Institucional da UNESP
Language:English
OAI Identifier:oai:repositorio.unesp.br:11449/176842
Online Access:http://dx.doi.org/10.1080/10428194.2018.1499905
http://hdl.handle.net/11449/176842
Access Level:Open access
Keyword:Biomarkers
chronic phase
gene expression regulation
imatinib mesylate
leukemia
microRNAs
myeloid
Philadelphia chromosome
Description
Summary:Chronic myeloid leukemia (CML) is a stem cell derived malignant disorder result of translocation t(9;22)(q34;q11) called Philadelphia chromosome (Ph+). microRNAS (miRNAs) are involved in several biological processes, altering the progression of various pathologies, including CML. This study evaluated whether circulating miRNAs display differential expression profiles in peripheral blood of CML-Chronic Phase (CML-CP) patients newly diagnosed in comparison with CML-CP treated with imatinib. We obtained peripheral blood samples from CML-CP Ph+ patients divided among group 1 (untreated newly diagnosed) and group 2 (treated with imatinib). A pool of total leukocytes from healthy donors was considered as control group. Expression analyses were performed for 768 miRNAs by RT-qPCR array. Bioinformatic tools were used to identify significant pathways and interaction networks. We found 80 deregulated miRNAs between the groups and, according to bioinformatic analysis, they are involved in different pathways, including molecular mechanisms of cancer. The study allows better understanding of disease molecular behavior, and it is useful for possible monitoring CML treatment and prognostic biomarkers identification.

Similar Items